New England Journal Of Medicine
Author:
Keywords:
Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Female, Humans, Lung Neoplasms, Male, Maximum Tolerated Dose, Middle Aged, Protein Kinase Inhibitors, Pyrimidines, Receptor Protein-Tyrosine Kinases, Recombination, Genetic, Sulfones, Treatment Outcome, Young Adult, Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, EML4-ALK FUSION GENE, KINASE INHIBITOR, ACQUIRED-RESISTANCE, CLINICAL RESISTANCE, MUTATION, EGFR, CRIZOTINIB, STI-571, Anaplastic Lymphoma Kinase, 11 Medical and Health Sciences, 32 Biomedical and clinical sciences, 42 Health sciences
Abstract:
Non-small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance invariably develops. Ceritinib (LDK378) is a new ALK inhibitor that has shown greater antitumor potency than crizotinib in preclinical studies.